NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: PPLPHARMA · data 2026-10-31
Piramal Pharma Limited
In plain words
Price: at or near its 52-week high.
Delivery: 34.3% of traded shares were kept for delivery over the last 10 sessions, against 40.0% over the last 60.
Latest results: a net profit of ₹6 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹9,779 cr |
| Net profit (last 12 months) | ₹-209 cr |
| Sales growth, 3 years (yearly) | 7.8% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 34.8% (-0.1 pts in a year), pledged 0.0%, institutions 28.1%.
ROE -4.0%, ROCE 1.3%, operating margin 3.2%: how much profit it earns on the money it uses.
Debt/equity 0.70, Profit growth — and sales growth 7.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-4.0%).
- Thin operating margin (3.2%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
PPLPHARMA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,617.06 crore, up 28.1% YoY and up 15.3% QoQ.
Net profit was ₹5.58 crore, a turn to profit from a loss a year ago and a turn to profit from a loss last quarter.
Operating margin was 13.3% (7.8% a year ago).
EPS was ₹0.04, positive against a negative EPS a year ago and positive against a negative EPS last quarter.
PPLPHARMA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,617.06 करोड़; पिछले साल की तुलना में 28.1% की बढ़त, पिछली तिमाही की तुलना में 15.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹5.58 करोड़; एक साल पहले के घाटे से मुनाफ़े में आया, पिछली तिमाही के घाटे से मुनाफ़े में आया।
ऑपरेटिंग मार्जिन: 13.3% (एक साल पहले 7.8%)।
EPS: ₹0.04; एक साल पहले के ऋणात्मक EPS से धनात्मक हुआ, पिछली तिमाही के ऋणात्मक EPS से धनात्मक हुआ।
PPLPHARMAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,617.06 કરોડ; ગયા વર્ષની સરખામણીએ 28.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 15.3% વધારો.
ચોખ્ખો નફો: ₹5.58 કરોડ; એક વર્ષ પહેલાંની ખોટમાંથી નફામાં આવી, ગયા ક્વાર્ટરની ખોટમાંથી નફામાં આવી.
ઓપરેટિંગ માર્જિન: 13.3% (એક વર્ષ પહેલાં 7.8%).
EPS: ₹0.04; એક વર્ષ પહેલાંના નકારાત્મક EPSથી હકારાત્મક થઈ, ગયા ક્વાર્ટરના નકારાત્મક EPSથી હકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
35/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 22.3% over the last 20 sessions vs 38.2% in the 40 before (0.58x); shares delivered per day 1.37x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 14 schemes hold it, about ₹375 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 9/15: Verdict "Building", sustained score 66/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Insider ● Dividend
- 27 Oct 26Results Q2 FY27 results: turned to profit vs a year ago +19.3% next session
- 27 Aug 26Insider SAST disclosure: Deutsche Bank AG, Mumbai Branch +1 acquired shares +3.5% next session
- 29 Jul 26Results Q1 FY27 results: loss narrowed vs a year ago +1.7% next session
- 28 Apr 26Results Q4 FY26 results: turned to loss vs a year ago -5.1% next session
- 29 Jan 26Results Q3 FY26 results: turned to loss vs a year ago +0.5% next session
- 5 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -0.5% next session
- 28 Jul 25Results Q1 FY26 results: loss narrowed vs a year ago +1.7% next session
- 16 Jul 25Dividend Dividend ₹0.14 (ex-date) +0.3% next session
- 14 May 25Results Q4 FY25 results: profit +51.6% YoY -2.9% next session
- 28 Jan 25Results Q3 FY25 results: profit −63.6% YoY +6.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹2,617 cr | ₹6 cr | — | 13.3% | 0.04 |
| Jun 2026 | ₹2,270 cr | ₹-69 cr | — | 8.6% | -0.52 |
| Mar 2026 | ₹2,752 cr | ₹-9 cr | -105.7% | 16.7% | -0.07 |
| Dec 2025 | ₹2,140 cr | ₹-136 cr | -3800.8% | 9.1% | -1.03 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 34.80% | 34.80% | 34.86% | 34.86% |
| Foreign institutions (FII) | 13.65% | 12.52% | 30.18% | 29.66% |
| Domestic institutions (DII) | 14.44% | 14.57% | 15.61% | 15.69% |
| Mutual funds | 12.71% | 13.18% | 14.12% | 14.03% |
| Retail investors | 9.62% | 11.02% | 10.44% | 10.49% |
| Number of shareholders | 4,13,197 | 4,61,096 | 4,50,661 | 4,53,830 |
Common questions
What was Piramal Pharma Limited's latest quarterly profit?
Piramal Pharma Limited reported a net profit of ₹6 cr for the quarter ended Sept 2026, on revenue of ₹2,617 cr.
How much do promoters hold in Piramal Pharma Limited?
Promoters held 34.80% of Piramal Pharma Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Piramal Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.7.
What is the 52-week high and low of Piramal Pharma Limited?
The 52-week high is ₹240 and the 52-week low is ₹132.3.
Mutual funds holding Piramal Pharma Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 14 schemes holding about ₹375 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 2.24% | ₹205 cr |
| NIPPON INDIA VALUE FUND | Nippon India Mutual Fund | 0.67% | ₹57 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 1.30% | ₹23 cr |
| NIPPON INDIA RETIREMENT FUND - WEALTH CREATION SCHEME | Nippon India Mutual Fund | 0.69% | ₹20 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.57% | ₹20 cr |
| ADITYA BIRLA SUN LIFE MANUFACTURING EQUITY FUND | Aditya Birla Sun Life Mutual Fund | 1.06% | ₹15 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.22% | ₹13 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.57% | ₹10 cr |
| ADITYA BIRLA SUN LIFE DIVIDEND YIELD FUND | Aditya Birla Sun Life Mutual Fund | 0.45% | ₹6 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.51% | ₹6 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.57% | ₹1 cr |
| Mirae Asset BSE Select IPO ETF | Mirae Asset Mutual Fund | 0.94% | ₹0 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.95% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.57% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Piramal Pharma Limited | ₹238.91 | ₹31,826 cr | — | 3.9 | -4% | 1.3% | 0.7 | +17.0% |
| GlaxoSmithKline Pharmaceuticals Limited | ₹2,494.3 | ₹42,073 cr | 39.6 | — | 49.1% | 52.8% | 0.01 | -5.9% |
| Emcure Pharmaceuticals Limited | ₹1,871.8 | ₹35,440 cr | 35.1 | — | 19.7% | 22.6% | 0.31 | +39.7% |
| Acutaas Chemicals Ltd | ₹4,003.6 | ₹32,770 cr | 75 | 17.7 | 24% | 28.9% | 0.02 | +137.3% |
| Wockhardt Limited | ₹1,901.1 | ₹30,809 cr | 75.5 | — | 4.6% | 5.3% | 0.45 | +44.7% |
| Neuland Laboratories Ltd. | ₹19,700 | ₹25,276 cr | 50.8 | — | 21.4% | 23.8% | 0.16 | +27.1% |
Compare PPLPHARMA with GLAXO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PPLPHARMA in NSE Scanner →